Article

Akorn seeks approval for ocular anesthetic

Buffalo Grove, IL-Akorn Inc.'s ocular anesthetic (AK-1015 [now named Akten]) has met its endpoints in a phase III trial. The four-arm, randomized, placebo-controlled trial tested three different doses.

Buffalo Grove, IL-Akorn Inc.'s ocular anesthetic (AK-1015 [now named Akten]) has met its endpoints in a phase III trial. The four-arm, randomized, placebo-controlled trial tested three different doses. All doses met the primary efficacy endpoint (ocular anesthesia) and the secondary endpoint (duration of anesthesia) with statistical significance, according to the company.

The unit-dose, preservative-free drug is intended for use in office-based and surgical ophthalmic procedures. It is manufactured at the company's facility in Somerset, NJ.

Once approved, the product will be marketed directly to ophthalmologists. The company filed a patent in October and intends to file a new drug application with the FDA in 2Q 2007.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.